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1. Introduction
  In recent 50 years, many countries have reported that the incidence 
and mortality of lung cancer have been significantly increased. 
The mortality of lung cancer is highest in malignant tumors, which 
seriously jeopardize people’s health[1]. And non-small-cell lung 
cancer (NSCLC) accounts for the vast majority of lung cancer 
(approximately 80%)[2]. Studies have showed that there has been 
gene mutation of epidermal growth factor receptor (EGFR) in about 
30% of NSCLC patients. Therefore EGFR gene mutation is the 
crucial factor of effective treatment in NSCLC patients, and closely 
related to the prognosis of them[3,4]. In this study, 297 patients were 
selected as objects, and the correlation between EGFR mutation, 
clinical characteristics and pathological features were analyzed.
2. Materials and methods 
2.1. Materials 
  A total of 297 NSCLC patients with confirmed diagnosis and 
complete information, admitted by our hospital during July 2009 to 
June 2010 were selected as research subjects. Then a retrospective 
analysis was taken on the clinical information of these patients. 
Among them, 204 men and 39 women aged between 35 and 78 
years, averagely aged (59.2依15.1) years. All patients met the 
following criteria: (1) There were measurable lesions in the lungs 
of all patients; (2) Expected survival were longer than 6 months; 
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(3) The case which complied with any one of the following need 
to be excluded: ① The patients who received pre-chemotherapy or 
other systemic anti-tumor therapy; ② The patients who suffered 
with other lung diseases, such as radioactive pulmonary disease, 
interstitial pneumonia; ③ Absolute neutrophil count<1.5伊109/L, 
platelets<100伊109/L; serum bilirubin>1.5伊 more the upper limit one 
of normal value (ULN); creatinine clearance<45 mL/min; ④  Either 
the patients who did not appear liver metastasis of lung cancer, 
and their alanine aminotransferase or aspartate aminotransferase> 
2.5伊 more the upper one limit of normal value (ULN). Or the 
patients who appeared liver metastasis of lung cancer, their alanine 
aminotransferase or aspartate aminotransferase> 5伊 more ULN; ⑤ 
Pregnant or lactating women;(4)All the patients participated in the 
study signed informed consent. And the study met the medical ethics 
criteria.
2.2. Methods
2.2.1. Data collection
  Clinical features included age, sex, smoking history (lifetime 
smoking quantity曒100 branches), family history of cancer (In two-
line three generations, someone suffered from certain malignant 
tumor) and clinical staging. Pathological features of patients included 
pathological type, degree of differentiation and tumor diameter. The 
prognosis included[5] tumor progression-free survival (PFS) and 
overall survival (OS). Follow-up endpoint was death. All follow-up 
were finished on October 2014.
2.2.2. EGFR gene mutation detection
  Fluorescence quantitative PCR was used to detect EGFR gene 
mutation of 297 patients. A total of 182 specimens were resected 
from surgery, 115 specimens were from bronchoscopic biopsy or 
percutaneous lung biopsy. Due to different sources of specimens, 
they were classified as paraffin section or non-paraffin section 
samples. The latter included fresh tissue of lesions, frozen sections of 
pathological diagnosis, non-heparin anticoagulated plasma, serum, 
non-heparin anticoagulated whole blood. Recommended DNA 
concentration of paraffin section samples was 2 ng/毺L-3 ng/毺L. 
A total of 9.4 ng-14.1 ng DNA was added into a single reaction tube 
as. According to the age limits of paraffin samples’ preservation, 9.4 
ng DNA was added into a single reaction tube whose age limit of 
preservation was less than three years. 14.1 ng DNA was added into 
a single reaction tube whose age limit of preservation was longer 
than three years. Recommended that DNA concentration of non-
paraffin section samples was 0.4 ng/毺L-1 ng/毺L. A total of 1.88 
ng-4.7 ng DNA was added into a single reaction tube. The mixed 
DNA samples were orderly added into 8-pore PCR reaction header 
pipets, covered with lids carefully, then centrifugated or lightly 
swung reaction in header pipets.
  Patients with drug susceptibility mutation caused by 19 deletions 
in exon 18 (G719S, G719A, G719C), exons 21 (L858R, L861Q), 
exons 20 (S768I) , exon 19 were selected as mutation group. Patients 
absent with mutation and with drug-resistant mutation caused 
by exon 20 (T790M, 20-ins) were selected as wild group. The 
correlation between clinical features and pathological features in 
patients with EGFR mutations was analyzed, and the prognoses of 
patients in two groups was compared.
2.2.3. Statistical analysis
  The data of study were processed and analyzed by using SPSS16.0 
software. Measurement data were analyzed by t test and represented 
as mean 依 sd. Count data were analyzed by 氈
2 test. Multivariate 
logistic regression analysis was used in correlation analysis. P<0.05 
was considered as statistically significant different.
3. Results
3.1. EGFR mutation test results
  There were 136 cases with mutation in all 297 patients. Among 
them, there were 8 cases of exon 18 mutation, 82 cases of exon 19 
mutation, 46 cases of exon 21 mutation, 2 cases of exon 18 and 19 
mutations, 4 cases of exon 19 and 21 mutations. There were 15 cases 
of exon 20 mutation in patients of wild type (Figure 1&2).
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Figure 1.  Curve of internal control reagent curve (VIC).
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Figure 2. Amplification curve of mutation sample (FAM).
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3.2. Multivariate analysis of EGFR gene mutation
  There were 59 patients with history of smoking and 45 patients 
with family history of tumor in 297 patients. There were 103 
patients at clinical stages 栺-栻, 194 patients at clinical stages 栿- 
桇; 47 patients of pathological type AB, 87 of type A, 84 of type B, 
79 of type O. There were 89 patients suffered from squamous cell 
carcinoma, 172 patients suffered from adenocarcinoma, and 36 cases 
with other types. There were 94 patients with well-differentiation, 
135 with intermediate differentiation, 68 with poorly differentiated. 
Tumor diameters of 69 patients were <3 cm , the ones of 118 patients 
were 3-8 cm, the ones of 110 patients were>8 cm.
  Clinical data, case data and EFGR gene mutations of patients were 
analysed by logistic regression analysis. There was no significant 
correlation with EFGR gene mutation and patients’ age, sex, smoking 
history, family history of tumor, clinical stage (P>0.05). There were 
significant correlation with the patients’ blood type, pathological 
type of tumor, degree of differentiation, tumor diameter and EGFR 
mutations (P <0.05) (Table 1).
3.3. EGFR gene mutation and prognosis of patients 
  According to the results of genetic mutations, the patients were 
divided into mutation group and wild type group. PFS of patients 
in mutation group were (23.6 依 5.4) months, OS were (29.6 依 
6.3) months. PFS of patients in wild type group were (17.8 依 4.9) 
months, OS were (24.2 依 5.7) months, the difference was statistically 
significant (P <0.05) (Figure 3).
140
120
100
80
60
40
20
0
0         10          20        30          40         50         60         70        80
Wild type group
Mutation group  
Figure 3. Comparison of survival curves in the two groups of patients. 
4. Discussion
  China’s annual emerging cases of tumor and deaths will reach 
2.68 million and 1.97 million in 2010. The number will be further 
increased to 3.49 million and 2.63 million[7]. Lung cancer is the top 
killer of malignant tumor, which has been a serious threat to the 
health of the population in this region[8]. Studies have shown that 
there are epidermal growth factor receptor gene mutations in 30% of 
NSCLC patients. And the mutation rate in women and non-smoking 
adenocarcinoma patients are even as high as 70%[9,10].
  EGFR gene mutations of 297 patients treated with ARMS were 
detected. Among them, there were 136 cases with mutation type 
(45.79%). Mutation was located on exon 18, exon 19 and exon 21. 
EFGR gene mutation, clinical features and pathological features 
of patients were analyzed by correlation analysis. There was no 
significant correlation with EFGR gene mutation and patients’ 
age, sex, smoking history, family history of tumor, clinical stage. 
There were significant correlation with the patients’ pathological 
type of tumor, degree of differentiation, tumor diameter and EGFR 
mutations. Gene mutation rates of patients with adenocarcinoma 
were up to 60.47% (104/172), significantly higher than ones in other 
types of tumors. The higher was the degree of tumor differentiation, 
the more increased was EGFR gene mutation. EGFR gene mutation 
reduced as patients’ tumor’ diameters increased.
  EGFR, a kind of transmembrane protein widely distributed on 
the cell surface, which belongs to receptor tyrosine kinase (TK) 
erbB / HER family, hold activity of tyrosine kinase[11]. EGFR 
can be combined with epidermal growth factor and then activate 
intracellular tyrosine kinase domain. It also can implement 
functions by PI3k-Akt and SOS-RAS-RAF-MEK-MAPK pathways. 
Meanwhile, EGFR plays an important role in division, proliferation, 
differentiation, migration, adhesion, anti-apoptosis, chemotherapy 
resistance and other processes in tumor cells[12,13]. The study found 
that EGFR gene mutations and targeted therapies drug sensitivity 
NSCLC patients showed had correlation[14]. In this study, PFS and 
OS of patients with EGFR mutations were significantly longer than 
Table 1 
Multivariate analysis of EGFR gene mutation.
Variable OR (95% CI) P
Age (≤60/>60) 0.785 (0.323-1.231) >0.05
Sex (male/female) 1.317 (0.973-1.587) >0.05
Smoking history (Y/N) 1.231 (0.876-1.374) >0.05
Family history of tumor  (Y/N) 1.414 (0.932-1.463) >0.05
Clinical stage (stage 栺-栻/stage 栿- 桇)
0.654 (0.345-1.043) >0.05
Blood type (AB/A,B, O) 0.147 (0.023-0.354) <0.05
Pathological type (squamous cell carcinoma、adenocarcinoma /others) 2.643 (2.112-3.344) <0.05
Degree of differentiation (well/intermediate, poorly) 0.221 (0.032-0.412) <0.05
Tumor diameter (<3/≥3) 0.196 (0.027-0.386) <0.05
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the ones of wild-type patients’, the prognosis of former were better.
  Study results announced by 2012 American Society of Clinical 
Oncology (ASCO) showed that EGFR mutation of NSCLC patients 
is one of the key factors in effective treatment and is closely related 
to the prognosis of patients[15]. At present, some EGFR-targeted 
chemotherapy drugs have emerged clinically, such as gefitinib. 
It is one kind of EGFR tyrosine kinase inhibitor (TKI) clinically 
often applied. It can be competitive binding EGFR and prevent 
phosphorylation of tyrosine residues, then promote tumor cell 
apoptosis, and further prevent the proliferation and spread of tumors 
by signaling transduction pathway[16,17]. The study found the EGFR 
mutations rate in female patients and patients with no previous 
history of smoking were higher and these patients could get more 
benefits from chemotherapy with EGFR-TKI.
  The study found that EGFR gene mutation was common in patients 
who were female, non-smoking, in earlier tumor stage, with smaller 
size and higher degree of differentiation tumor. It was more common 
in patients with adenocarcinoma. And pathological features of 
patients were independent predictors of EGFR mutations. The 
prognosis of patients with EGFR mutation was significantly better 
than the one of wild-type patients.
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